Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus - PubMed

Affiliations

• PMID: 12567308
• DOI: 10.1086/367643

Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus

Carmen Martinez-Sierra et al. Clin Infect Dis. 2003.

Abstract

To evaluate the factors associated with the evolution of chronic hepatitis C in human immunodeficiency virus (HIV)-infected patients, a cross-sectional analysis of 41 HIV-infected patients with chronic hepatitis C (known as "HIV-HCV [hepatitis C virus]-coinfected patients") and a control group of patients with chronic hepatitis C who did not have HIV infection (known as "non-HIV-infected patients") was performed. The association of histological variables with demographic parameters, HCV load and genotype, HIV load, CD4(+) T cell count, and response to highly active antiretroviral therapy (HAART) was evaluated. HIV-HCV-coinfected patients showed a significantly higher HCV load, more-advanced fibrosis, and a higher liver fibrosis progression rate (FPR) than did non-HIV-infected patients. A high HCV load and a low CD4(+) T cell count were associated with a higher FPR. The immune response induced by HAART did not influence this progression. In conclusion, HIV-HCV-infected patients, mainly such patients with a high HCV load and an immunodepressed state, have a higher FPR. An independent effect of the immune response to HAART was not evident.

Comment in

• Human immunodeficiency virus and hepatitis C virus: which is the cart, and which is the horse?

  Jenny-Avital ER. Jenny-Avital ER. Clin Infect Dis. 2003 Sep 1;37(5):739; author reply 740. doi: 10.1086/377176. Clin Infect Dis. 2003. PMID: 12942414 No abstract available.

Similar articles

• Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.

  Macías J, Mira JA, López-Cortés LF, Santos I, Girón-González JA, González-Serrano M, Merino D, Hernández-Quero J, Rivero A, Merchante N, Trastoy M, Carrillo-Gómez R, Arizcorreta-Yarza A, Gómez-Mateos J, Pineda JA. Macías J, et al. Antivir Ther. 2006;11(7):839-46. Antivir Ther. 2006. PMID: 17302246

• HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.

  Reiberger T, Ferlitsch A, Sieghart W, Kreil A, Breitenecker F, Rieger A, Schmied B, Gangl A, Peck-Radosavljevic M. Reiberger T, et al. J Viral Hepat. 2010 Jun;17(6):400-9. doi: 10.1111/j.1365-2893.2009.01197.x. Epub 2009 Sep 15. J Viral Hepat. 2010. PMID: 19780945

• Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

  Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group. Antonucci G, et al. Clin Infect Dis. 2005 Jun 15;40(12):e101-9. doi: 10.1086/430445. Epub 2005 May 5. Clin Infect Dis. 2005. PMID: 15909251

• Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.

  Pineda JA, Macías J. Pineda JA, et al. J Antimicrob Chemother. 2005 Apr;55(4):417-9. doi: 10.1093/jac/dkh555. Epub 2005 Feb 24. J Antimicrob Chemother. 2005. PMID: 15731202 Review.

• HIV/HCV co-infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article.

  Petrovic LM. Petrovic LM. Liver Int. 2007 Jun;27(5):598-606. doi: 10.1111/j.1478-3231.2007.01478.x. Liver Int. 2007. PMID: 17498243 Review.

Cited by

• Generalized Liver- and Blood-Derived CD8+ T-Cell Impairment in Response to Cytokines in Chronic Hepatitis C Virus Infection.

  Burke Schinkel SC, Carrasco-Medina L, Cooper CL, Crawley AM. Burke Schinkel SC, et al. PLoS One. 2016 Jun 17;11(6):e0157055. doi: 10.1371/journal.pone.0157055. eCollection 2016. PLoS One. 2016. PMID: 27315061 Free PMC article.

• Evaluation of a Series of Lipidated Tucaresol Adjuvants in a Hepatitis C Virus Vaccine Model.

  Belz TF, Olson ME, Giang E, Law M, Janda KD. Belz TF, et al. ACS Med Chem Lett. 2020 Oct 29;11(12):2428-2432. doi: 10.1021/acsmedchemlett.0c00413. eCollection 2020 Dec 10. ACS Med Chem Lett. 2020. PMID: 33335664 Free PMC article.

• Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.

  Petersen T, Lee YJ, Osinusi A, Amorosa VK, Wang C, Kang M, Matining R, Zhang X, Dou D, Umbleja T, Kottilil S, Peters MG. Petersen T, et al. AIDS Res Hum Retroviruses. 2016 Jul;32(7):660-7. doi: 10.1089/aid.2015.0236. Epub 2016 Mar 14. AIDS Res Hum Retroviruses. 2016. PMID: 26974581 Free PMC article. Clinical Trial.

• Role of GB virus C in modulating HIV disease.

  Schwarze-Zander C, Blackard JT, Rockstroh JK. Schwarze-Zander C, et al. Expert Rev Anti Infect Ther. 2012 May;10(5):563-72. doi: 10.1586/eri.12.37. Expert Rev Anti Infect Ther. 2012. PMID: 22702320 Free PMC article. Review.

• Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients.

  Schiavini M, Angeli E, Mainini A, Uberti-Foppa C, Zerbi P, Sagnelli C, Cargnel A, Vago G, Duca PG, Giorgi R, Rizzardini G, Gubertini G. Schiavini M, et al. Hepat Mon. 2011 Jul 1;11(7):525-31. Hepat Mon. 2011. PMID: 22706343 Free PMC article.

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program